Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics - - Two proprietary, adv...
EF Hutton analyst Elemer Piros reiterates Small Pharma (TSXV:DMT) with a Buy and maintains C$5 price target.
EF Hutton analyst Elemer Piros reiterates Small Pharma (TSXV:DMT) with a Buy and maintains C$5 price target.
EF Hutton analyst Elemer Piros reiterates Small Pharma (TSXV:DMT) with a Buy and maintains C$5 price target.
EF Hutton analyst Elemer Piros reiterates Small Pharma (TSXV:DMT) with a Buy and maintains C$5 price target.
EF Hutton analyst Elemer Piros reiterates Small Pharma (TSXV:DMT) with a Buy and maintains C$5 price target.
EF Hutton analyst Elemer Piros reiterates Small Pharma (TSXV:DMT) with a Buy and raises the price target from C$2.5 to C$5.
EF Hutton analyst Elemer Piros initiates coverage on Small Pharma (TSXV:DMT) with a Buy rating and announces Price Target of...
The Week In Psychedelics: MindMed Launches MDMA Program For Social Anxiety And Autism
